

TIDOMET FORTE

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
Abbreviated Prescribing information for TIDOMET FORTE (Carbidopa 25 mg / Levodopa 250 mg tablets) [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Levodopa, the metabolic precursor of dopamine, converted to dopamine in the brain and act as antiparkinsonian agent. Carbidopa inhibits decarboxylation of peripheral levodopa. It does not cross the blood brain barrier; hence it makes more levodopa available for transport to the brain.

INDICATION: For treatment of Parkinson's disease and syndrome. **DOSAGE AND**

ADMINISTRATION: Patients not receiving levodopa: the initial dose is one-half tablet taken once or twice daily and fully effective doses usually are reached within seven days as compared to weeks or months with levodopa alone. Patients not receiving levodopa: Discontinue levodopa at least 12hrs (24 hrs for slow-release preparations) and dose of combination should be approx.20% of the previous levodopa dose. Maintenance dose: one tablet three or four times a day. **CONTRAINDICATIONS:** contraindicated with

Nonselective monoamine oxidase (MAO) inhibitors, narrow-angle glaucoma, in patients with known hypersensitivity to any component of this medication and severe psychoses.

WARNINGS & PRECAUTIONS Neuroleptic malignant syndrome (NMS), central nervous system (CNS) effects, e.g., dyskinesias (involuntary movements), hyperpyrexia and confusion, impulse control/compulsive behaviors, hallucinations/psychotic-like behavior, depression and melanoma. **DRUG INTERACTIONS** Interacts with

antihypertensive agents, antidepressants, anticholinergics, monoamine oxidase inhibitors, dopamine D₂ receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone), isoniazid and iron salts. **ADVERSE REACTIONS:** Syncope, chest pain, anorexia, cardiac irregularities and/or palpitations, orthostatic effects including hypotensive episodes, hypertension, phlebitis, vomiting, gastro-intestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, angioedema, urticaria, pruritus, neuroleptic malignant syndrome, bradykinetic episodes (the "on-off" phenomenon), dizziness, paraesthesia, psychotic episodes including delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dyspnea, alopecia, rash, dyspepsia, dry mouth, bitter taste, sialorrhoea, dysphagia, bruxism, hiccups, abdominal pain and distress, constipation, flatulence, weight gain or loss, oedema, psychotic episodes including delusions, hallucinations and paranoid ideation, confusion, agitation, somnolence, dream abnormalities including nightmares, insomnia, paresthesia, headache, depression with or without development of suicidal tendencies, dementia, flushing, increased sweating, diplopia, blurred vision, dilated pupils, urinary retention, urinary incontinence, priapism, weakness, faintness, fatigue.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/TIDOMET FORTE/250,25mg/May-15/01/AbPI

(Additional information is available on request)